Literature DB >> 7186068

Gastric acid hypersecretion in cystic fibrosis.

K L Cox, J N Isenberg, M E Ament.   

Abstract

Increased basal and/or pentagastrin-stimulated gastric acid secretion was observed in 31 of 40 cystic fibrosis (CF) patients as compared to 13 age-matched control volunteers. Fasting serum gastrin level for 20 CF patients of 67.7 +/- 11.1 pg/ml (ranging from 10 to 145 pg/ml) was normal. Meal-stimulated serum gastrin concentrations were not significantly higher for seven CF patients as compared to nine normal subjects. In a rat bioassay, serum extracts from six CF patients produced gastric acid secretion comparable to 250 ng/ml of pentagastrin; significantly (p less than 0.01) greater than the responses produced by serum extracts from six normal subjects. There was no significant correlation of severity of pulmonary disease or steatorrhea with acid secretory results. Fourteen of 16 CF patients biopsied had evidence of proximal small intestinal injury which correlated with basal acid output elevation. Gastric acid hypersecretion in CF patients is due to nongastrin secretagogues and is a cause of proximal small intestinal injury.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7186068     DOI: 10.1097/00005176-198212000-00019

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  23 in total

Review 1.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

2.  Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.

Authors:  Stefanie Hennig; Claire E Wainwright; Scott C Bell; Hugh Miller; Lena E Friberg; Bruce G Charles
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Diuretic effect and disposition of furosemide in cystic fibrosis.

Authors:  J Prandota; I J Smith; B C Hilman; J T Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.

Authors:  S K Dutta; V S Hubbard; M Appler
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

Review 5.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 6.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

7.  In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.

Authors:  Robert J Kuhn; Sabine Eyting; Friederike Henniges; Andreas Potthoff
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

8.  Cellular bicarbonate protects rat duodenal mucosa from acid-induced injury.

Authors:  Y Akiba; O Furukawa; P H Guth; E Engel; I Nastaskin; P Sassani; R Dukkipatis; A Pushkin; I Kurtz; J D Kaunitz
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

9.  Children with cystic fibrosis have prolonged chemical clearance of acid reflux compared to symptomatic children without cystic fibrosis.

Authors:  Frederick W Woodley; Rodrigo S Machado; Don Hayes; Carlo Di Lorenzo; Ajay Kaul; Beth Skaggs; Karen McCoy; Alpa Patel; Hayat Mousa
Journal:  Dig Dis Sci       Date:  2013-11-28       Impact factor: 3.199

10.  Effect of intrajejunal acidity on aqueous phase bile acid and lipid concentrations in pancreatic steatorrhoea due to cystic fibrosis.

Authors:  P L Zentler-Munro; W J Fitzpatrick; J C Batten; T C Northfield
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.